Curated News
By: NewsRamp Editorial Staff
June 04, 2025
Clinilabs Strengthens Leadership Team to Drive CNS Innovation
TLDR
- Clinilabs strengthens its executive team with David Hagerman as CFO and Jeanine Falinski as SVP of Commercial Development, positioning the company for strategic growth and competitive advantage in CNS drug development.
- Clinilabs appoints David Hagerman, with 25 years in financial leadership, as CFO and Jeanine Falinski, with 20 years in pharma, as SVP of Commercial Development to enhance its financial and commercial operations.
- By expanding its leadership team, Clinilabs reinforces its commitment to advancing CNS therapies, promising better treatments for psychiatric, neurological, and substance use disorders worldwide.
- Clinilabs' new executive hires bring decades of expertise to drive innovation in CNS drug development, marking a significant step forward in medical research and patient care.
Impact - Why it Matters
The strategic appointments at Clinilabs signal a robust phase of growth and innovation in CNS drug and technology development. For stakeholders in the healthcare and pharmaceutical industries, this move underscores the increasing importance of specialized expertise in addressing complex CNS disorders. Patients and healthcare providers stand to benefit from accelerated development and approval of new therapies, potentially improving outcomes for those affected by psychiatric, neurological, and substance use disorders.
Summary
Clinilabs, LLC, a prominent full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and medical technology development, has announced the addition of two key executives to its leadership team. David Hagerman joins as Chief Financial Officer (CFO), bringing over 25 years of financial leadership experience from the life sciences and IT sectors, including roles at X-Chem, Charles River Laboratories, and Parexel. Jeanine Falinski, MBA, is appointed as Senior Vice President of Commercial Development, leveraging her 20 years of pharmaceutical industry experience to enhance Clinilabs' commercial capabilities. These strategic appointments highlight Clinilabs' commitment to bolstering its leadership and commercial strategies to support its growth and expansion in the CNS field.
Dr. Gary Zammit, President and CEO of Clinilabs, expressed enthusiasm about the new appointments, noting their potential to drive the company's mission forward. Clinilabs is renowned for its focus on CNS drug, device, and technology development, having conducted over 800 CNS clinical trials and contributed to the approval of 23 new therapies across 14 CNS indications since 2000. The company's dedication to advancing treatments for psychiatric, neurological, and substance use disorders, as well as rare CNS diseases, underscores its pivotal role in the healthcare sector.
Source Statement
This curated news summary relied on content disributed by citybiz. Read the original source here, Clinilabs Strengthens Leadership Team to Drive CNS Innovation
